Last updated: February 19, 2026
This report analyzes World Intellectual Property Organization (WIPO) patent application WO2017006855, detailing its scope, key claims, and relevant patent landscape. The application, filed by Glaxo Group Limited, concerns novel pharmaceutical compounds and their use in treating inflammatory diseases.
What is the core innovation described in WO2017006855?
The central innovation disclosed in WO2017006855 is a class of novel heterocyclic compounds, specifically substituted pyrimidines, that act as potent and selective inhibitors of Bruton's tyrosine kinase (BTK) [1]. BTK is a key enzyme in B-cell receptor signaling, making its inhibition a therapeutic strategy for B-cell malignancies and autoimmune diseases. The patent claims provide chemical structures for these compounds, pharmaceutical compositions containing them, and methods of using them to treat various inflammatory and autoimmune conditions.
The application defines a genus of compounds with a general formula (I) [1]:
R1
|
/ \
N---N
| |
C---C=N
/ \ / \
R2 C R3
|
X
Where R1, R2, R3, and X represent various substituted groups, including but not limited to alkyl, aryl, heteroaryl, and halogens. Specific examples of compounds are provided within the patent to illustrate the scope of the invention. These examples detail precise chemical structures and their characterization data.
The disclosed compounds are characterized by their ability to inhibit BTK activity. The patent provides in vitro data demonstrating the inhibitory potency of selected compounds against BTK. This potency is quantified by IC50 values, indicating the concentration of the compound required to inhibit 50% of the target enzyme activity. The patent asserts that the compounds exhibit desirable pharmacological profiles, including high selectivity for BTK over other kinases, which is crucial for minimizing off-target effects and improving the safety profile of potential therapeutics.
What specific claims are asserted in WO2017006855?
WO2017006855 asserts several distinct claims related to the novel compounds, their preparation, and their therapeutic applications. The claims are structured hierarchically, starting with broad definitions and progressively narrowing to specific embodiments.
What are the primary compound claims?
Claim 1 of the application defines the core chemical entities. It claims "A compound of formula (I) or a pharmaceutically acceptable salt thereof" [1]. Formula (I) is a broad heterocyclic structure with multiple variable substituents (R1, R2, R3, X). This claim encompasses a wide range of related structures, providing a broad intellectual property fence around the general chemical class.
Dependent claims further define specific ranges and types of substituents for R1, R2, R3, and X. For instance, other claims may specify that R1 is an alkyl group of 1-6 carbons, or that X is a substituted phenyl ring. These dependent claims narrow the scope to more specific chemical entities, often corresponding to the exemplified compounds.
What are the claims related to pharmaceutical compositions and methods of use?
Beyond the chemical compounds themselves, WO2017006855 also claims pharmaceutical compositions and methods of treatment.
-
Pharmaceutical Compositions: Claims are directed to "A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier" [1]. These claims cover formulations designed for therapeutic administration, including various dosage forms such as tablets, capsules, injectables, and topical preparations. The compositions may also include other therapeutically active agents.
-
Methods of Treatment: The patent claims methods of treating various diseases by administering the inventive compounds. These methods are directed towards conditions mediated by BTK activity, particularly inflammatory and autoimmune disorders. Specific diseases mentioned include rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, immune thrombocytopenia (ITP), and multiple sclerosis [1]. The claims typically describe "A method of treating a disease in a subject, comprising administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof" [1].
Are there claims related to manufacturing or processes?
While the primary focus of WO2017006855 is on the compounds and their therapeutic use, it may also include claims related to processes for preparing these compounds. These claims would typically detail specific synthetic routes or key intermediates used in the manufacturing process, aiming to protect the methods of production. For example, a claim might cover "A process for preparing a compound of formula (I)" [1], outlining specific reaction steps and reagents.
What is the patent landscape surrounding BTK inhibitors and WO2017006855?
The patent landscape for Bruton's tyrosine kinase (BTK) inhibitors is highly competitive and dynamic. WO2017006855, filed by Glaxo Group Limited, is situated within this complex terrain, facing competition from established players and emerging innovators.
Who are the key patent holders in the BTK inhibitor space?
Several pharmaceutical companies hold significant patent portfolios for BTK inhibitors. These include:
- AbbVie Inc.: Known for its approved BTK inhibitor, ibrutinib (Imbruvica). AbbVie has a strong patent position covering the compound itself, its formulations, and methods of use for various B-cell malignancies and autoimmune conditions.
- BeiGene, Ltd.: Developed zanubrutinib (Brukinsa), another important BTK inhibitor. BeiGene holds patents related to zanubrutinib's structure, synthesis, and therapeutic applications, particularly in hematological cancers.
- AstraZeneca PLC: Has developed acalabrutinib (Calquence), a second-generation BTK inhibitor. AstraZeneca's patents cover acalabrutinib's chemical structure, manufacturing, and clinical uses.
- Eli Lilly and Company: While not as prominent in the approved BTK space as the above, Lilly has also been active in BTK inhibitor research and holds patents in this area.
- Novartis AG: Has explored BTK inhibitors, particularly for autoimmune indications.
WO2017006855, originating from Glaxo Group Limited, indicates GlaxoSmithKline's (GSK) interest in this therapeutic class. GSK has a history of developing innovative pharmaceuticals and seeks to establish a patent position for novel BTK inhibitors with potentially improved profiles.
How does WO2017006855 compare to existing BTK inhibitor patents?
WO2017006855 claims a novel class of substituted pyrimidine compounds. Its patentability and competitive positioning depend on its novelty and inventive step compared to existing BTK inhibitor patents.
- Structural Novelty: The patent asserts that the claimed compounds are structurally distinct from previously disclosed BTK inhibitors. This distinction is crucial for overcoming prior art and obtaining patent protection. The specific heterocyclic scaffold and substituent patterns are key to establishing this novelty.
- Functional Differentiation: Beyond structural differences, the patent likely emphasizes improved pharmacological properties. This could include enhanced potency, increased selectivity for BTK, better pharmacokinetic profiles (e.g., oral bioavailability, half-life), or reduced off-target toxicities compared to existing inhibitors. Evidence supporting these advantages is critical for demonstrating an inventive step.
- Therapeutic Indication: While many BTK inhibitors are developed for B-cell malignancies, WO2017006855 specifically highlights applications in inflammatory and autoimmune diseases. This focus on non-oncological indications could represent a strategic differentiation, targeting a market segment where existing BTK inhibitors may have limitations or where new mechanisms are sought.
The patent landscape is characterized by both composition of matter patents (claiming the molecules themselves) and method of use patents (claiming specific therapeutic applications). WO2017006855, as a composition of matter patent application, aims to secure broad protection for its novel chemical entities.
What are the potential implications of WO2017006855 for R&D and investment?
The filing of WO2017006855 suggests a strategic R&D direction by Glaxo Group Limited into the BTK inhibitor space, with a specific emphasis on inflammatory and autoimmune indications.
- R&D Strategy: For Glaxo Group Limited, this application represents an investment in developing next-generation BTK inhibitors that could offer advantages over current therapies. The focus on autoimmune diseases suggests a strategy to broaden the therapeutic application of BTK inhibition beyond oncology, a significant unmet medical need.
- Investment Opportunities: Companies holding patents for novel BTK inhibitors with potentially differentiated profiles attract significant investment interest. The success of WO2017006855, if granted, would position Glaxo Group Limited to potentially develop and commercialize a new class of drugs in a high-value market. Investors would assess the strength of the patent claims, the preclinical and clinical data supporting efficacy and safety, and the competitive landscape for these indications.
- Competitive Landscape Impact: The existence of novel BTK inhibitors targeting autoimmune diseases could intensify competition. It may prompt other companies to explore similar therapeutic avenues or develop strategies to circumvent existing patents. This could lead to further innovation and patent filings in the field.
- Licensing and Collaboration: Patents like WO2017006855 can be valuable assets for licensing or collaboration agreements. Glaxo Group Limited could partner with other pharmaceutical companies to accelerate the development and commercialization of its patented compounds, particularly for specific indications or geographical regions.
The patent landscape for BTK inhibitors is characterized by continuous innovation. WO2017006855 is a marker of Glaxo Group Limited's participation in this innovative space, aiming to carve out a unique position through novel chemical entities and targeted therapeutic applications.
Key Takeaways
WO2017006855 describes novel substituted pyrimidine compounds with BTK inhibitory activity. The patent application claims these compounds, pharmaceutical compositions containing them, and methods for treating inflammatory and autoimmune diseases. The BTK inhibitor patent landscape is crowded, with major pharmaceutical companies holding significant intellectual property. WO2017006855 distinguishes itself by targeting inflammatory and autoimmune indications, distinct from the primary oncological focus of many existing BTK inhibitors. This patent application reflects Glaxo Group Limited's R&D strategy and has potential implications for investment, licensing, and competitive dynamics within the pharmaceutical industry.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds described in WO2017006855?
The primary therapeutic target is Bruton's tyrosine kinase (BTK).
-
What specific types of diseases does WO2017006855 propose to treat with its claimed compounds?
The patent application proposes treating inflammatory and autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, immune thrombocytopenia (ITP), and multiple sclerosis.
-
What is the chemical class of the novel compounds claimed in WO2017006855?
The novel compounds are substituted pyrimidines.
-
Which company filed the patent application WO2017006855?
Glaxo Group Limited filed the patent application.
-
How does WO2017006855 aim to differentiate itself from existing BTK inhibitors in the market?
It aims to differentiate by focusing on the therapeutic applications in inflammatory and autoimmune diseases, suggesting potentially improved profiles or broader utility beyond the established oncological applications of many current BTK inhibitors.
Citations
[1] Glaxo Group Limited. (2017). Heterocyclic compounds as BTK inhibitors. World Intellectual Property Organization. WO2017006855 A1.
